Search hospitals > New York > Commack
Memorial Sloan Kettering Commack
Claim this profileCommack, New York 11725
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Lymphoma
Conducts research for Adenocarcinoma
682 reported clinical trials
191 medical researchers
Summary
Memorial Sloan Kettering Commack is a medical facility located in Commack, New York. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Lymphoma, Adenocarcinoma and other specialties. Memorial Sloan Kettering Commack is involved with conducting 682 clinical trials across 575 conditions. There are 191 research doctors associated with this hospital, such as Christopher J. Forlenza, Andrea Cercek, MD, Thomas Kaley, MD, and Nancy Lee, MD.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderStage IV
HER2 positive
HER2 negative
Top PIs
Christopher J. ForlenzaMemorial Sloan Kettering Cancer Center7 years of reported clinical research
Expert in Lymphoma
Expert in Langerhans Cell Histiocytosis
18 reported clinical trials
38 drugs studied
Andrea Cercek, MDMemorial Sloan Kettering Cancer Center4 years of reported clinical research
Expert in Colorectal Cancer
Studies Rectal Cancer
15 reported clinical trials
31 drugs studied
Thomas Kaley, MDMemorial Sloan Kettering Cancer Center5 years of reported clinical research
Studies Brain Tumor
Studies Glioblastoma
14 reported clinical trials
22 drugs studied
Nancy Lee, MDMemorial Sloan Kettering Cancer Center1 year of reported clinical research
Studies Cancer
Studies Squamous Cell Carcinoma
13 reported clinical trials
30 drugs studied
Clinical Trials running at Memorial Sloan Kettering Commack
Breast Cancer
Gastroesophageal Junction Adenocarcinoma
Esophageal Adenocarcinoma
Esophageal Carcinoma
Lymphoma
Cancer
Prostate Cancer
Diffuse Large B-Cell Lymphoma
Colorectal Cancer
Lung Cancer
Radiation + Pembrolizumab + Olaparib
for Breast Cancer
The purpose of this study is to find out whether adding pembrolizumab, with or without olaparib, to standard radiation therapy is a safe and effective treatment for metastatic breast cancer, , and to see whether the study treatment is better than, the same as, or worse than the usual approach (radiation therapy alone).
Recruiting3 awards Phase 210 criteria
Radiation and HER2-Targeted Therapy
for Breast Cancer
This Phase III trial compares the recurrence-free interval (RFI) among patients with early-stage, low risk HER2+ breast cancer who undergo breast conserving surgery and receive HER2-directed therapy, and are randomized to not receive adjuvant breast radiotherapy versus those who are randomized to receive adjuvant radiotherapy per the standard of care.
Recruiting2 awards Phase 315 criteria
Omitting Radiation Therapy
for Breast Cancer
The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back.
Recruiting2 awards Phase 319 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Memorial Sloan Kettering Commack?
Memorial Sloan Kettering Commack is a medical facility located in Commack, New York. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Lymphoma, Adenocarcinoma and other specialties. Memorial Sloan Kettering Commack is involved with conducting 682 clinical trials across 575 conditions. There are 191 research doctors associated with this hospital, such as Christopher J. Forlenza, Andrea Cercek, MD, Thomas Kaley, MD, and Nancy Lee, MD.
Where is Memorial Sloan Kettering Commack located?
Memorial Sloan Kettering Commack is situated at 650 Commack Road, Commack, NY 11725. Access is convenient via the Long Island Expressway (I-495), taking Exit 53 and proceeding north on Commack Road, where the hospital is located on the right side.
Who should I call to ask about financial aid or insurance network?
**Memorial Sloan Kettering Commack Hospital Contact Information:**
- **Financial Assistance:** Call Patient Financial Services at 212-639-3810 or visit a representative at:
- Rockefeller Outpatient Pavilion, 160 East 53rd Street, 3rd floor
- 64th Street Outpatient Center, 205 East 64th Street, Lower Concourse
- Evelyn H. Lauder Breast Center, 300 East 66th Street, 1st Floor
- The Sidney Kimmel Center for Prostate and Urologic Cancers, 353 East 68th Street, 1st floor
- Main Hospital, 1275 York Ave, Room A104 (near the 67th Street entrance)
- **Insurance Questions:** Call Patient Billing Services at 646-497-9176 or email [billing@mskcc.org](mailto:billing@mskcc.org).
- **Prescription Assistance Programs:** Contact your doctor’s office to meet with your Patient Access Coordinator.
- **International Patients:** Call the International Center at 212-639-4900 or use AT&T Direct Access by dialing the access number for your country, then 888-675-7722.
- **General Inquiries:** Call 212-639-2000.
What insurance does Memorial Sloan Kettering Commack accept?
Memorial Sloan Kettering Cancer Center (MSK) accepts a variety of insurance plans, including but not limited to Medicare, Medicaid, and commercial plans from Aetna, Blue Cross Blue Shield, Cigna, and many others. It's important to verify that your specific plan includes MSK in its network by reviewing the list of participating insurance plans or contacting MSK directly. Patients are also encouraged to confirm their coverage and financial responsibility with their insurance company.
What awards or recognition has Memorial Sloan Kettering Commack received?
Memorial Sloan Kettering Cancer Center, including its Commack location, is celebrated for its pioneering research and exceptional patient care, emphasizing safety and innovative treatments. The center's scientists are recipients of prestigious awards, such as the Marie-Josée Kravis Women in Science Endeavor (Kravis WiSE) fellowship grants. It boasts one of the country's largest clinical trials programs for cancer, offering patients early access to the latest treatments.